Global News

PatientsLikeMe names Marni Hall senior vice president

Monday, July 11, 2016

PatientsLikeMe has appointed Marni Hall, Ph.D., MPH, as its new senior vice president of Research and Policy. A distinguished research scientist and public policy expert, Hall will develop and direct the strategies and teams focused on expanding the role of real-world evidence in precision medicine, and in the research agendas of PatientsLikeMe and its customers.

[Read More]

David Meek appointed Ipsen’s chief executive officer

Monday, July 11, 2016

The board of directors of Ipsen appointed David Meek as chief executive officer, effective July 18, 2016. On this date, Marc de Garidel will assume the role of non-executive chairman and will continue to serve the board of directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.

[Read More]

NCI, CRUK, Wellcome partner on cancer models to accelerate research

Monday, July 11, 2016

An international project to develop a large, globally accessible bank of new cancer cell culture models for the research community has launched. The National Cancer Institute (NCI), part of the NIH; Cancer Research U.K., London; the Wellcome Trust Sanger Institute, Cambridge, England; and the foundation Hubrecht Organoid Technology, Utrecht, Netherlands, are joining forces to develop the Human Cancer Models Initiative (HCMI), which will bring together expertise from around the world to make about 1,000 cancer cell models.

[Read More]

Patient-centricity v. patient recruitment: One in the same?

Monday, July 11, 2016

The Pulse on Site Success by Christophe Berthoux

It is no surprise that delays in clinical trial timelines can largely be attributed to issues with patient recruitment and retention. Research has shown that nine out of 10 clinical trials eventually meet their enrollment goals; however, reaching these goals usually increases timelines by double what was originally intended. A 2013 study from the Tufts Center for the Study of Drug Development found that most sponsors and CROs rely on a limited number of traditional recruitment methods and have yet to embrace newer, non-traditional strategies, such as social media campaigns.

[Read More]

PureTech expands scientific advisory board team and advisory group

Friday, July 8, 2016

PureTech Health, a cross-disciplinary biotech company developing novel medicines at the interface of the gut, brain and immune system, has announced the appointment of Feng Zhang, Ph.D., to its scientific advisory board (SAB). The company has also appointed Jeff Stevens, as vice president of Growth Strategy & Operations and has expanded its team of senior advisors to include Meghan Fitzgerald, DrPH, executive vice president of Corporate Strategy, M&A and Health Policy at Cardinal Health; Atul Pande, M.D., former senior vice president and head of Neurosciences at GlaxoSmithKline; and Philip J. Larsen, M.D., Ph.D., global head of Diabetes Research & Development at Sanofi.

[Read More]